- Home
- RPAY vs OTLK Comparison
RPAY vs OTLK Comparison
Compare RPAY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | OTLK |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.1M | 249.6M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RPAY | OTLK |
|---|---|---|
| Price | $4.24 | $1.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $5.53 | $2.50 |
| AVG Volume (30 Days) | 710.9K | ★ 15.2M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $309,261,000.00 | $8,146,123.00 |
| Revenue This Year | $12.54 | $1,430.98 |
| Revenue Next Year | $4.66 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.16 |
| 52 Week High | $5.90 | $3.39 |
Technical Indicators
Market Signals| Indicator | RPAY | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 68.17 | 59.67 |
| Support Level | $3.25 | $0.26 |
| Resistance Level | $5.32 | $1.54 |
| Average True Range (ATR) | 0.21 | 0.23 |
| MACD | 0.11 | -0.03 |
| Stochastic Oscillator | 78.21 | 42.11 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.